S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01

22nd Century Group Stock Forecast, Price & News

-0.04 (-1.59%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.65 million shs
Average Volume
2.41 million shs
Market Capitalization
$401.96 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive XXII News and Ratings via Email

Sign-up to receive the latest news and ratings for 22nd Century Group and its competitors with MarketBeat's FREE daily newsletter.

22nd Century Group logo

About 22nd Century Group

22nd Century Group, Inc. is a biotechnology company, which develops disruptive plant-based solutions for life science, consumer product, and pharmaceutical markets. It focuses on technologies that alter the level of nicotine in tobacco plants and level of cannabinoids in hemp or cannabis plants through genetic engineering, gene-editing, and modern plant breeding techniques. The company was founded on September 12, 2005 and is headquartered in Buffalo, NY.


22nd Century Group (NYSEAMERICAN:XXII) Stock Price Down 3.6%
December 28, 2021 |  americanbankingnews.com
22nd Century Shares Pop On FDA Marketing Authorization
December 23, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$28.10 million
Book Value
$0.32 per share


Net Income
$-19.71 million
Pretax Margin




Free Float
Market Cap
$401.96 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.80 out of 5 stars

Consumer Staples Sector

119th out of 184 stocks

Cigarettes Industry

5th out of 6 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

22nd Century Group (NASDAQ:XXII) Frequently Asked Questions

Is 22nd Century Group a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 22nd Century Group in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" 22nd Century Group stock.
View analyst ratings for 22nd Century Group
or view top-rated stocks.

Are investors shorting 22nd Century Group?

22nd Century Group saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 12,520,000 shares, an increase of 51.0% from the December 15th total of 8,290,000 shares. Based on an average daily volume of 3,480,000 shares, the short-interest ratio is presently 3.6 days.
View 22nd Century Group's Short Interest

When is 22nd Century Group's next earnings date?

22nd Century Group is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for 22nd Century Group

How were 22nd Century Group's earnings last quarter?

22nd Century Group, Inc. (NASDAQ:XXII) announced its quarterly earnings data on Thursday, November, 4th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.02. The biotechnology company had revenue of $7.81 million for the quarter, compared to analysts' expectations of $8 million. 22nd Century Group had a negative net margin of 82.69% and a negative trailing twelve-month return on equity of 38.09%.
View 22nd Century Group's earnings history

What price target have analysts set for XXII?

2 brokerages have issued 1 year target prices for 22nd Century Group's stock. Their forecasts range from $5.00 to $8.50. On average, they expect 22nd Century Group's share price to reach $6.75 in the next year. This suggests a possible upside of 173.3% from the stock's current price.
View analysts' price targets for 22nd Century Group
or view top-rated stocks among Wall Street analysts.

Who are 22nd Century Group's key executives?

22nd Century Group's management team includes the following people:
  • James A Mish, Chief Executive Officer
  • Michael J. Zercher, President & Chief Operating Officer
  • Richard F. Fitzgerald, Chief Financial Officer
  • Juan Sanchez Tamburrino, Vice President-Research & Development
  • Steven P. Przybyla, Secretary, Vice President & General Counsel

What other stocks do shareholders of 22nd Century Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 22nd Century Group investors own include Aurora Cannabis (ACB), Alteryx (AYX), Auxly Cannabis Group (CBWTF), (CGC), Charlotte's Web (CWBHF), Enphase Energy (ENPH), Inseego (INSG), Luckin Coffee (LKNCY), MediPharm Labs (MEDIF) and MercadoLibre (MELI).

What is 22nd Century Group's stock symbol?

22nd Century Group trades on the NASDAQ under the ticker symbol "XXII."

How do I buy shares of 22nd Century Group?

Shares of XXII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 22nd Century Group's stock price today?

One share of XXII stock can currently be purchased for approximately $2.47.

How much money does 22nd Century Group make?

22nd Century Group has a market capitalization of $401.96 million and generates $28.10 million in revenue each year. The biotechnology company earns $-19.71 million in net income (profit) each year or ($0.17) on an earnings per share basis.

How many employees does 22nd Century Group have?

22nd Century Group employs 67 workers across the globe.

What is 22nd Century Group's official website?

The official website for 22nd Century Group is www.xxiicentury.com.

Where are 22nd Century Group's headquarters?

22nd Century Group is headquartered at 9530 Main St, CLARENCE, NY 14031-1915, United States.

How can I contact 22nd Century Group?

22nd Century Group's mailing address is 9530 Main St, CLARENCE, NY 14031-1915, United States. The biotechnology company can be reached via phone at (716) 270-1523, via email at [email protected], or via fax at 716-877-3064.

This page was last updated on 1/18/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.